Fig. 6: Antibiotic susceptibility of non-phage treated isolates recovered from systemic infection in vivo model. | Nature Communications

Fig. 6: Antibiotic susceptibility of non-phage treated isolates recovered from systemic infection in vivo model.

From: Exploiting lung adaptation and phage steering to clear pan-resistant Pseudomonas aeruginosa infections in vivo

Fig. 6

Difference in inhibition zone diameter in millimetres compared to the input P. aeruginosa to a panel of antibiotics for isolates recovered from the a lung, b liver, c blood, d kidney and e spleen. The mean with SD is indicated and n = 3 isolates tested per group f shows a summary of changes in resistance classification according to EUCAST breakpoints. g Minimum Inhibitory Concentration (MIC) of tobramycin and meropenem determined via E-Test for input and in vivo adapted isolates, with fold reduction in MIC shown using a colour scheme (white: no change, dark blue: 10-fold change). Panel of antibiotics included: Piperacillin (PRL), Piperacillin-tazobactam (PTZ), Ticarcillin (TC), Ticarcillin-clavulanic acid (TIM), Cefepime (CPM), Ceftazidime (CAZ), Ceftolozane-tazaobactam (C/T), Imipenem (IMI), Meropenem (MEM), Aztreonam (ATM), Ciprofloxacin (CIP), Levofloxacin (LEV), Amikacin (AK), Tobramycin (TN). Source data are provided as a Source Data file.

Back to article page